Palvella Therapeutics, Inc. - PVLA
About Gravity Analytica
Recent News
- 09.24.2025 - Palvella Therapeutics Conference Call to Discuss Expansion of QTORIN™ Rapamycin Pipeline to Include Clinically Significant Angiokeratomas
- 09.24.2025 - Palvella Therapeutics Conference Call to Discuss Expansion of QTORIN™ Rapamycin Pipeline to Include Clinically Significant Angiokeratomas
- 09.24.2025 - Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
- 09.24.2025 - Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
- 09.17.2025 - Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy
- 09.17.2025 - Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy
- 09.15.2025 - Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
- 09.15.2025 - Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
- 09.09.2025 - Trevor Allred
- 09.09.2025 - Trevor Allred